Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.026
Neutral
RSI(14)
51.605
Neutral
STOCH(KDJ)(9,3,3)
21.840
Neutral
ATR(14)
0.108
Low Volatility
CCI(14)
-103.919
Sell
Williams %R
79.310
Sell
TRIX(12,20)
0.721
Sell
StochRSI(14)
41.110
Buy
Rockwell Medical Inc
RMTI1.060USD
+0.060+6.00%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
41.77MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Rockwell Medical Inc
Currency: USD Updated: 2026-02-06Key Insights
Rockwell Medical Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 87 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 3.75.In the medium term, the stock price is expected to remain stable.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Rockwell Medical Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Rockwell Medical Inc Highlights
StrengthsRisks
Rockwell Medical, Inc. is a healthcare company. The Company develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. The Company operates in the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceuticals, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream. The Company is the supplier of liquid and dry, acid and bicarbonate concentrates for dialysis patients in the United States. The Company manufactures hemodialysis concentrates at its facilities in Michigan, South Carolina, and Texas, and the Company manufactures its dry acid concentrate mixers at its facility in Iowa.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 39.39% year-on-year.
Fairly Valued
The company’s latest PE is -6.45, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 3.56M shares, decreasing 49.71% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 562.21K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.92.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
3.750
Target Price
+275.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Rockwell Medical Inc is 7.70, ranking 102 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 15.93M, representing a year-over-year decrease of 43.75%, while its net profit experienced a year-over-year decrease of 205.35%.
Score
Financials
7.43
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.41
Operational Efficiency
10.00
Growth Potential
6.46
Shareholder Returns
7.19
Rockwell Medical Inc's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Rockwell Medical Inc is 8.71, ranking 9 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -6.45, which is -91.57% below the recent high of -0.54 and -22330.85% above the recent low of -1447.06.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 87/159
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Rockwell Medical Inc is 8.00, ranking 57 out of 159 in the Pharmaceuticals industry. The average price target is 3.75, with a high of 5.00 and a low of 2.50.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
3.750
Target Price
+275.00%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
173
Total
6
Median
8
Average
Company name
Ratings
Analysts
Rockwell Medical Inc
RMTI
2
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Eli Lilly and Co
LLY
33
Vertex Pharmaceuticals Inc
VRTX
33
Gilead Sciences Inc
GILD
31
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Rockwell Medical Inc is 5.92, ranking 135 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 1.26 and the support level at 0.89, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.070
Sell
MA10
1.088
Sell
MA20
1.069
Sell
MA50
0.971
Buy
MA100
1.054
Buy
MA200
1.082
Sell
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of Rockwell Medical Inc is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 9.03%, representing a quarter-over-quarter decrease of 49.95%. The largest institutional shareholder is The Vanguard, holding a total of 1.40M shares, representing 3.55% of shares outstanding, with 0.76% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Irrevocable Larson Family Investment Trust
Geode Capital Management, L.L.C.
Strobeck (Mark)
BlackRock Institutional Trust Company, N.A.
Ravich (Mark H)
Radie (Robert Samuel)
Timmins (Megan Carden)
Nissenson Allen R
1
2
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Rockwell Medical Inc is 2.80, ranking 118 out of 159 in the Pharmaceuticals industry. The company's beta value is 1.69. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.69
VaR
+6.99%
240-Day Maximum Drawdown
+55.80%
240-Day Volatility
+103.26%
Return
Best Daily Return
60 days
+31.62%
120 days
+31.62%
5 years
+31.62%
Worst Daily Return
60 days
-9.04%
120 days
-17.39%
5 years
-39.14%
Sharpe Ratio
60 days
+0.75
120 days
+0.47
5 years
-0.10
Risk Assessment
Maximum Drawdown
240 days
+55.80%
3 years
+87.20%
5 years
+92.80%
Return-to-Drawdown Ratio
240 days
-0.71
3 years
-0.09
5 years
-0.19
Skewness
240 days
+1.59
3 years
+0.47
5 years
+0.46
Volatility
Realised Volatility
240 days
+103.26%
5 years
+105.17%
Standardised True Range
240 days
+8.69%
5 years
+21.27%
Downside Risk-Adjusted Return
120 days
+98.87%
240 days
+98.87%
Maximum Daily Upside Volatility
60 days
+79.22%
Maximum Daily Downside Volatility
60 days
+57.47%
Liquidity
Average Turnover Rate
60 days
+2.34%
120 days
+1.56%
5 years
--
Turnover Deviation
20 days
+291.51%
60 days
+84.63%
120 days
+23.26%
Peer Comparison
Pharmaceuticals
Rockwell Medical Inc
RMTI
6.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mckesson Corp
MCK
9.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.92 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.86 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.70 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
